🎉 M&A multiples are live!
Check it out!

Gossamer Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Gossamer Bio and similar public comparables like Julphar, Benevolent AI, and Galapagos.

Gossamer Bio Overview

About Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.


Founded

2015

HQ

United States of America
Employees

145

Website

gossamerbio.com

Financials

LTM Revenue $87.9M

LTM EBITDA -$86.6M

EV

$93.1M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Gossamer Bio Financials

Gossamer Bio has a last 12-month revenue of $87.9M and a last 12-month EBITDA of -$86.6M.

In the most recent fiscal year, Gossamer Bio achieved revenue of $115M and an EBITDA of -$40.0M.

Gossamer Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Gossamer Bio valuation multiples based on analyst estimates

Gossamer Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $115M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$162M -$40.0M XXX XXX XXX
EBITDA Margin -Infinity% -35% XXX XXX XXX
Net Profit -$229M -$180M XXX XXX XXX
Net Margin -Infinity% -157% XXX XXX XXX
Net Debt $107M $177M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Gossamer Bio Stock Performance

As of April 15, 2025, Gossamer Bio's stock price is $1.

Gossamer Bio has current market cap of $185M, and EV of $93.1M.

See Gossamer Bio trading valuation data

Gossamer Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$93.1M $185M XXX XXX XXX XXX $-0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Gossamer Bio Valuation Multiples

As of April 15, 2025, Gossamer Bio has market cap of $185M and EV of $93.1M.

Gossamer Bio's trades at 1.1x LTM EV/Revenue multiple, and -1.1x LTM EBITDA.

Analysts estimate Gossamer Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Gossamer Bio and 10K+ public comps

Gossamer Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $93.1M XXX XXX XXX
EV/Revenue 0.8x XXX XXX XXX
EV/EBITDA -2.3x XXX XXX XXX
P/E -3.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -26.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Gossamer Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Gossamer Bio Valuation Multiples

Gossamer Bio's NTM/LTM revenue growth is -63%

Gossamer Bio's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Gossamer Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Gossamer Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Gossamer Bio and other 10K+ public comps

Gossamer Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -35% XXX XXX XXX XXX
EBITDA Growth -75% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -98% XXX XXX XXX XXX
Revenue per Employee $0.8M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 32% XXX XXX XXX XXX
R&D Expenses to Revenue 121% XXX XXX XXX XXX
Opex to Revenue 152% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Gossamer Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Gossamer Bio M&A and Investment Activity

Gossamer Bio acquired  XXX companies to date.

Last acquisition by Gossamer Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Gossamer Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Gossamer Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Gossamer Bio

When was Gossamer Bio founded? Gossamer Bio was founded in 2015.
Where is Gossamer Bio headquartered? Gossamer Bio is headquartered in United States of America.
How many employees does Gossamer Bio have? As of today, Gossamer Bio has 145 employees.
Who is the CEO of Gossamer Bio? Gossamer Bio's CEO is Mr. Faheem Hasnain.
Is Gossamer Bio publicy listed? Yes, Gossamer Bio is a public company listed on NAS.
What is the stock symbol of Gossamer Bio? Gossamer Bio trades under GOSS ticker.
When did Gossamer Bio go public? Gossamer Bio went public in 2019.
Who are competitors of Gossamer Bio? Similar companies to Gossamer Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Gossamer Bio? Gossamer Bio's current market cap is $185M
What is the current revenue of Gossamer Bio? Gossamer Bio's last 12-month revenue is $87.9M.
What is the current EBITDA of Gossamer Bio? Gossamer Bio's last 12-month EBITDA is -$86.6M.
What is the current EV/Revenue multiple of Gossamer Bio? Current revenue multiple of Gossamer Bio is 1.1x.
What is the current EV/EBITDA multiple of Gossamer Bio? Current EBITDA multiple of Gossamer Bio is -1.1x.
Is Gossamer Bio profitable? Yes, Gossamer Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.